TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05902520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DP CD8 TIL
Description: intravenous infusion of T cell suspension

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DP CD8 TIL KD
Description: intravenous infusion of T cell suspension

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose IL-2
Description: Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
Study: NCT06004219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer counseling group
Description: A community advisory board (CAB) will be set up for need assessment and to design the peer support program. Virtual meetings will be held quarterly for year 1 and 2. The group will consist of (up to 12 members) and will include at least 2 patient partners (patients with a recently diagnosed ulcer), 2 peer pals (patients with a healed DFU), family members or caregivers (limited to only 1 person per family represented on the CAB), healthcare workers (podiatrist, nurse, or case manager), medical equipment company representatives, and others. We will ask them about potential barriers at the first meeting, have flexible meeting times, and intentionally limit the number of healthcare providers. At the last meeting, we will seek feedback and input from the CAB. In addition, this group will have the opportunity to participate in a focus group which will be moderated with a trained, bilingual assistant and will last 40-60 minutes.
Study: NCT05065983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP, adjuvanted
Description: Adjuvanted formulation includes aluminum hydroxide
Study: NCT05411107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of sputum sample

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of sputum sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Brush Biopsy
Description: Undergo bronchial brush biopsy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchial Brush Biopsy
Description: Undergo bronchial brush biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchoscopy
Description: Undergo bronchoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Given PO
Study: NCT06049615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLAAS® System
Description: The CLAAS® System delivers a plug to the ostia of the Left Atrial Appendage (LAA) and is designed to occlude the appendage to eliminate blood flow. It is designed to conform to the geometry of the LAA. The implant is designed to permanently seal off the LAA from the LA with an endothelial layer that forms across the LA face of the implant. The implant is available in two different sizes; Regular (27mm) and Large (35mm) to accommodate patient anatomy. Angiography and/or echocardiography may be used to determine the LAA ostium diameter to properly select the Implant size. The implant has an inner, cylindrical, Nitinol endoskeleton that provides the mechanical base structure. The Nitinol endoskeleton contains 10 face struts and 20 anchors (Regular) and 12 struts and 24 anchors (Large) facing proximally to engage the tissue to resist movement. The endoskeleton also provides the conformable structure to enable the foam cylinder to compress against the LAA tissue to facilitate sealing.
Study: NCT05946954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Dentoalveolar Restoration
Description: Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ice cream cone technique
Description: Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability
Study: NCT05902520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose IL-2
Description: Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
Study: NCT06273410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cention N
Description: Cention N will be manipulated using the standard powder: liquid ratio which is, one scoop of powder with one drop of liquid. Powder and liquid will be dispensed on the mixing pad and mixed using a plastic spatula according to the manufacturer's instruction for 45-60 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cention N + Adhesive
Description: Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulk Fill Composite
Description: Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds.
Study: NCT05517356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailored management strategies
Description: Our basic surgical strategies for the central repair operations for ATAAD are as follows. As arterial lines for cardiopulmonary bypass, side branches of the axillary and femoral arteries were used. Circulatory arrest was established when the nasopharyngeal temperature reached 25°C. Anterograde selective cerebral perfusion was performed through the right axillary artery, and the brain was perfused at approximately 5 mL/kg/min. The extent of aortic replacement was determined according to the extent of dissection involvement.~For malperfused patients with symptom onset within 6 hours, the immediate central repair was performed followed by repeat CTA postoperatively, and endovascular reperfusion was applied if the malperfusion persisted. While for patients with symptom onset beyond 6 hours, delayed central repair were performed after the organ functions improved.
Study: NCT06114225

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy
Description: participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
Study: NCT05738603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index
Description: Hemodynamic perioperative monitoring with the Hypotension Prediction Index
Study: NCT02487134

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIGR Matrix
Description: Reinforcement of the suture line with resorbable mesh

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Closure of the abdomen with conventional technique
Study: NCT05109702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Tanfanercept Ophthalmic Solution
Description: Tanfanercept ophthalmic solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vehicle solution.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo vehicle solution.
Study: NCT05411107

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04874584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTNSM
Description: The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy Education
Description: Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
Study: NCT05463159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
Study: NCT04780841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX013
Description: RDX013 is an experimental drug that is a potassium secretagogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX013
Description: RDX013 is an experimental drug that is a potassium secretagogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX013
Description: RDX013 is an experimental drug that is a potassium secretagogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX013
Description: RDX013 is an experimental drug that is a potassium secretagogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX013
Description: RDX013 is an experimental drug that is a potassium secretagogue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment that looks identical to experimental treatment
Study: NCT05084508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine low potency
Description: 1 dose of a low-potency investigational varicella vaccine administered subcutaneously in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine medium potency
Description: 1 dose of a medium-potency investigational varicella vaccine administered subcutaneously in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational varicella vaccine high potency
Description: 1 dose of a high-potency investigational varicella vaccine administered subcutaneously in the upper arm
Study: NCT05463159

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
Study: NCT04950140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia
Description: Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery for the Treatment of Parastomal Hernia
Description: Laparoscopic Surgery for the Treatment of Parastomal Hernia in Cancer Patients
Study: NCT06122987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II and hydrocortisone sodium succinate
Description: Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
Study: NCT04889963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adypose mesenchymal conditioned medium and ligament derived conditioned medium
Description: rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adypose mesenchymal conditioned medium and ligament derived conditioned medium
Description: rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adypose mesenchymal conditioned medium and ligament derived conditioned medium
Description: rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adypose mesenchymal conditioned medium and ligament derived conditioned medium
Description: rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
Study: NCT05467462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V carbetocin administration
Description: Group I: carbetocin was intravenously administered immediately after birth of the baby.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Oxytocin administration
Description: Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V carbetocin and tranexamic acid administration
Description: Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V Oxytocin and tranexamic acid administration
Description: Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
Study: NCT04695548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentric contraction exercise
Description: The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric contraction exercise
Description: The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric contraction exercise
Description: The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic passive stretching
Description: The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
Study: NCT05411107

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05084508

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed varicella vaccine Lot 1
Description: 1 dose of a marketed varicella vaccine of Lot 1 administered subcutaneously in the upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed varicella vaccine Lot 2
Description: 1 dose of a marketed varicella vaccine of Lot 2 administered subcutaneously in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: 1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm
Study: NCT05394103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q901
Description: The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q901
Description: The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q901
Description: The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab)
Description: KEYTRUDA® (pembrolizumab) will be administered Q6W
Study: NCT05084508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: 1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: 1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, mumps, and rubella vaccine
Description: 1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: 1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: 1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh
Study: NCT05706649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: 21 day diet that excludes any form of meat and other animal products, including dairy products.
Study: NCT05124353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
Study: NCT05529251

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy boost
Description: Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~* 20 Gy if no more disease is visible (node \< 1 cm in large diameter)~* 24 Gy for nodes \<= 2 cm~* 30 Gy for nodes \> 2 cm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC7
Description: Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
Study: NCT05084508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: 1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh